Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine

World Journal of Gastroenterology

Volumn 21, Issue 15, 2015, Pages 4644-4651

  Bowden, Scott ^a   Locarnini, Stephen ^a   Chang, Ting Tsung ^b   Chao, You Chen ^c   Han, Kwang Hyub ^d   Gish, Robert G ^e,f,g   De Man, Robert A ^h   Yu, Miao ⁱ   Llamoso, Cyril ⁱ   Tang, Hong ^j  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d Yonsei University College of Medicine   (South Korea)

^e PJM Consulting LLC   (United States)

^f ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^g HEPATITIS B FOUNDATION   (United States)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ Bristol Myers Squibb   (United States)

^j Research and Development   (United States)

more..

Author keywords

Antiviral suppression; Hepatitis B virus; Intrahepatic hepatitis B virus DNA; Nucleos(t)ide analog therapy; Virologic cure

Indexed keywords

ALANINE AMINOTRANSFERASE; COVALENTLY CLOSED CIRCULAR DNA; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS DNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CIRCULAR DNA; GUANINE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENDER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; ISHAK FIBROSIS SCORE; KNODELL NECROINFLAMMATORY SCORE; LINEAR REGRESSION ANALYSIS; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECTS; GENETICS; LIVER; MIDDLE AGED; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BIOMARKERS; BIOPSY; DNA, CIRCULAR; DNA, VIRAL; DOUBLE-BLIND METHOD; DOWN-REGULATION; FEMALE; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LINEAR MODELS; LIVER; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84928196119     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i15.4644     Document Type: Article

References (43)

1. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat 2009; 16: 453-463 [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x]
2. Caruntu FA, Molagic V. CccDNA persistence during natural evolution of chronic VHB infection. Rom J Gastroenterol 2005; 14: 373-377 [PMID: 16400354]
3. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42: 302-308 [PMID: 15710212 DOI: 10.1016/j.jhep.2004.12.015]
4. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006; 44: 694-702 [PMID: 16941694 DOI: 10.1002/hep.21299]
5. Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason WS. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001; 75: 311-322 [PMID: 11119601]
6. Yuen MF, Wong DK, Sablon E, Tse E, Ng IO, Yuan HJ, Siu CW, Sander TJ, Bourne EJ, Hall JG, Condreay LD, Lai CL. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects. Hepatology 2004; 39: 1694-1701 [PMID: 15185311 DOI: 10.1002/hep.20240]
7. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, Delaney WE, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-1758 [PMID: 15188170]
8. Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 2011; 17: 4853-4857 [PMID: 22171125 DOI: 10.3748/wjg.v17.i44.4853]
9. Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol 2010; 52: 594-604 [PMID: 20185200 DOI: 10.1016/j.jhep.2009.10.033]
10. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
11. Matsuzaki T, Tatsuki I, Otani M, Akiyama M, Ozawa E, Miuma S, Miyaaki H, Taura N, Hayashi T, Okudaira S, Takatsuki M, Isomoto H, Takeshima F, Eguchi S, Nakao K. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol 2013; 28: 1217-1222 [PMID: 23432697 DOI: 10.1111/jgh.12182]
12. Hosaka T, Suzuki F, Kobayashi M, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int 2010; 30: 1461-1470 [PMID: 20840396 DOI: 10.1111/j.1478-3231.2010.02344.x]
13. Zoulim F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15 [PMID: 15451174]
14. Block TM, Gish R, Guo H, Mehta A, Cuconati A, London WT, Guo JT. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res 2013; 98: 27-34 [PMID: 23391846 DOI: 10.1016/j.antiviral.2013.01.006]
15. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther 2006; 11: 909-916 [PMID: 17302253]
16. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531 [PMID: 15470215]
17. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009; 49: S13-S21 [PMID: 19399811 DOI: 10.1002/hep.22881]
18. Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 2013; 11: 1004-1010.e1 [PMID: 23376799 DOI: 10.1016/j.cgh.2013.01.026]
19. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020 [PMID: 16525138]
20. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010 [PMID: 16525137]
21. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carrilho FJ, Poordad F, Halota W, Horsmans Y, Tsai N, Zhang H, Tenney DJ, Tamez R, Iloeje U. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430 [PMID: 20049753 DOI: 10.1002/hep.23327]
22. Chang TT, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]
23. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, Wichroski MJ, Xu D, Yang J, Wilber RB, Colonno RJ. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514 [PMID: 19280622 DOI: 10.1002/hep.22841]
24. Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11: 361-368 [PMID: 22233350 DOI: 10.1517/14740338.2012.653340]
25. Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58: 1537-1547 [PMID: 23389810 DOI: 10.1002/hep.26301]
26. Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-765 [PMID: 22490523 DOI: 10.1136/gutjnl-2012-302024]
27. Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013; 58: 98-107 [PMID: 23213040 DOI: 10.1002/hep.26180]
28. Yang SC, Lee CM, Hu TH, Wang JH, Lu SN, Hung CH, Changchien CS, Chen CH. Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. J Antimicrob Chemother 2013; 68: 2154-2163 [PMID: 23620466 DOI: 10.1093/jac/dkt147]
29. Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol 2013; 58: 427-433 [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025]
30. Sung JJ, Wong ML, Bowden S, Liew CT, Hui AY, Wong VW, Leung NW, Locarnini S, Chan HL. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 2005; 128: 1890-1897 [PMID: 15940624]
31. McClune AC, Tong MJ. Chronic hepatitis B and hepatocellular carcinoma. Clin Liver Dis 2010; 14: 461-476 [PMID: 20638025 DOI: 10.1016/j.cld.2010.05.009]
32. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]
33. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
34. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatol Int 2012; 6: 531-561 [DOI 10.1007/s12072-012-9365-4]
35. Cheng PN, Liu WC, Tsai HW, Wu IC, Chang TT, Young KC. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents. J Med Virol 2011; 83: 602-607 [PMID: 21328373 DOI: 10.1002/jmv.22014]
36. Takkenberg B, Terpstra V, Zaaijer H, Weegink C, Dijkgraaf M, Jansen P, Beld M, Reesink H. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir. J Gastroenterol Hepatol 2011; 26: 1527-1535 [PMID: 21557773 DOI: 10.1111/j.1440-1746.2011.06766.x]
37. Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684 [PMID: 16941693]
38. Marciano S, Galdame OA, Gadano AC. HBV genotype F: natural history and treatment. Antivir Ther 2013; 18: 485-488 [PMID: 23792712 DOI: 10.3851/IMP2604]
39. Senior JR. Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future. Clin Pharmacol Ther 2012; 92: 332-339 [PMID: 22871997 DOI: 10.1038/clpt.2012.108]
40. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. J Hepatol 2011; 55: 1121-1131 [PMID: 21718667 DOI: 10.1016/j.jhep.2011.06.006]
41. Gish RG, Chang TT, Lai CL, de Man RA, Gadano A, Llamoso C, Tang H. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir. Antivir Ther 2013; 18: 691-698 [PMID: 23510982 DOI: 10.3851/IMP2559]
42. Cai D, Mills C, Yu W, Yan R, Aldrich CE, Saputelli JR, Mason WS, Xu X, Guo JT, Block TM, Cuconati A, Guo H. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012; 56: 4277-4288 [PMID: 22644022 DOI: 10.1128/AAC.00473-12]
43. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014; 343: 1221-1228 [PMID: 24557838 DOI: 10.1126/science.1243462]